Bland Blueprint for Biotech

Industrial Biotechnology in Europe: Issues for Public Policy. Duncan Davies, ed. Frances Pinter, London, 1986. 156 PP. £22.50. Distributed in North America by Longwood Publishing Group, Dover, NH. $30 HB, $14.50 PB. In 1967 Jean-Jacques Servan Schreiber published the instant best seller The American Challenge, which argued that Europe's weakness in high-technology industries could lead to economic stagnation and loss of political self-determination. Since this call for action, it has become

Written byGeorge Poste
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

This volume, which describes the proceedings of a conference in Brussels in November 1985 organized by the European Economic Community Center for European Studies, is a survey of current approaches to commercial biotechnology. It also attempts to outline an action plan to improve European competitiveness.

At first sight the breadth of topics is impressive. On more detailed examination, however, the content, with few exceptions, is bland and uncritical. The need to define a clear strategy for the future of European biotechnology in the public and private sectors emerges as a common theme, but the message is not emphasized with sufficient clarity or forcefulness.

It is difficult to identify the intended readership. Scientists who have even a limited knowledge of biotechnology will find little that is novel in the chapters describing potential applications of biotechnology. The reader is merely provided with lengthy lists of how specific industries will be "revolutionized" by ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies